Oncology
Pretreatment vascular endothelial growth factor profiles metastatic non-small cell lung cancer
Published in Clinical Oncology Week, November 28th, 2005
According to researchers in Germany, "in the present study, we investigated the prognostic value of VEGF and matrix metalloproteinase (MMP)-9 serum levels in patients with metastatic NSCLC. From September 1999 to June 2001, pretreatment serum levels of VEGF and MMP-9 were analyzed in 194 patients of a randomized phase III trial with enzyme-linked immunoassays."
"Patients with a VEGF serum level higher than the median serum level (10,995 pg/ml) had a significantly shorter overall survival than those with a lower serum level (p=.04). The MMP-9...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Prognostics
General prognostic models underestimated mortality risk in critically ill cancer patients - Radiotherapy
Radiation therapy used to treat unresected stage I-II non-small cell lung cancer - Surgery
Partial adrenalectomy can preserve adrenocortical function in adrenal pheochromocytoma patients - Surgery
Radical retropubic prostatectomy performed in prostate cancer patients younger than 50 years of age - Adenosine Deaminase
Prognostic ability of adenosine deaminase activity studied - Adverse Drug Reaction
Magnesium supplementation mitigates cetuximab-induced hypomagnesemia - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
